Antifungal susceptibility testing of Trichosporon beigelii to imidazole compounds.
Twenty-two strains of Trichosporon beigelii have been tested for susceptibility to imidazole compounds. Ten strains were isolated from untreated genital white piedra lesions and 12 were from the same patients following treatment failure with imidazole compounds. Agar dilution and disk elution methods were compared using two media: yeast nitrogen base and antibiotic assay medium 3 (Difco). Antifungal agents tested were econazole, miconazole, ketoconazole, clotrimazole, and amphotericin B in concentrations of 0.0625-32 micrograms/mL. The most consistent results occurred with antibiotic assay medium 3 and the agar dilution method giving minimal inhibitory concentrations between 0.0625 and 0.25 micrograms/mL. Using yeast nitrogen base agar, minimal inhibitory concentrations were higher ranging from 0.0625 to 2.0 micrograms/mL. End points of growth in the disk elution method were not clearly delineated and ranged from 0.0625 to 8.0 micrograms/mL. The distribution of minimal inhibitory concentrations obtained using different media and methods were compared by chi 2 analysis, and the medium was found to significantly change the minimal inhibitory concentrations. There was no difference in the susceptibility of strains of T. beigelii to imidazole compounds whether isolated before or after treatment. It was concluded that in vitro susceptibility of T. beigelii to imidazole compounds did not necessarily predict efficacy in vivo.
McBride
M E
ME
Department of Dermatology, Baylor College of Medicine, Houston, TX 77030.
Kalter
D C
DC
Wolf
J E
JE
D000666:Amphotericin B / Q000494:pharmacology; D003022:Clotrimazole / Q000494:pharmacology; D003470:Culture Media; D004464:Econazole / Q000494:pharmacology / Q000627:therapeutic use; D005832:Genital Diseases, Male / Q000188:drug therapy / Q000382:microbiology*; D006197:Hair; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D007654:Ketoconazole / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008825:Miconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D003904:Mitosporic Fungi / Q000187:drug effects*; D009181:Mycoses / Q000382:microbiology*; D010854:Piedra / Q000188:drug therapy / Q000382:microbiology*; D012611:Scrotum; D014250:Trichosporon / Q000187:drug effects*
D003470:Culture Media; D007093:Imidazoles; D004464:Econazole; D008825:Miconazole; D000666:Amphotericin B; D003022:Clotrimazole; D007654:Ketoconazole